Sugi Predict

Sugi Predict / Compounds / SCHEMBL29455643

SCHEMBL29455643

SCHEMBL29455643

CN1Cc2ccccc2C1=O

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.63
▸ NPC1 O15118 3/20 0.55
▸ RAB9A P51151 3/20 0.55
▸ PKM P14618 2/20 0.53
▸ KDM4E B2RXH2 3/20 0.50
▸ ALOX15 P16050 2/20 0.50
▸ TSHR P16473 2/20 0.50
▸ SIRT1 Q96EB6 1/20 0.50
▸ BRD4 O60885 1/20 0.50
▸ CREBBP Q92793 1/20 0.50
▸ PARP1 P09874 1/20 0.46
▸ RNASEH1 O60930 1/20 0.46
▸ HRH1 P35367 2/20 0.45
▸ SLC6A4 P31645 1/20 0.45
▸ HTT P42858 1/20 0.45
▸ SMN1; SMN2 Q16637 1/20 0.45
▸ ALDH1A1 P00352 1/20 0.45
▸ XIAP P98170 1/20 0.45
▸ HKDC1 Q2TB90 1/20 0.45
▸ HSD17B10 Q99714 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL470341 1.00 KMT2A (0.63) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL21212239 0.98 KMT2A (0.61) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL30467294 0.84 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL30467298 0.84 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL20274268 0.80 KMT2A (0.42) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL22612117 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL22612116 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL31383689 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL25905963 0.80 KMT2A (0.46) KMT2ANPC1RAB9APKMKDM4E
SCHEMBL27325981 0.80 ESR1 (0.46) KMT2ARAB9AKDM4EALOX15TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260069605-A1 KRAS INHIBITORS INCYTE CORP (US) 2026-03-12 — — US disclosed
US-12357603-B2 Acyl sulfonamides for treating cancer BAYER AKTIENGESELLSCHAFT (DE) 2025-07-15 — — US disclosed
CN-115697993-B Pyrimidine compounds as AXL inhibitors 南京正大天晴制药有限公司 2024-12-10 — — CN disclosed
EP-4450493-A1 PYRIMIDINE OR PYRIDINE DERIVATIVE AND MEDICINAL USE THEREOF Signet Therapeutics Inc. (CN) 2024-10-23 — — EP disclosed
US-20240327412-A1 FACTOR XIIA INHIBITORS KALVISTA PHARMACEUTICALS LIMITED (GB) 2024-10-03 — — US disclosed
CN-118525015-A Compounds as FAK inhibitors and uses thereof 微境生物医药科技(上海)有限公司 2024-08-20 — — CN disclosed
CN-113474340-B Novel isoindolinone substituted indoles and derivatives as RAS inhibitors 勃林格殷格翰国际有限公司 2024-07-23 — — CN disclosed
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors FORMA THERAPEUTICS, INC. (US) 2024-07-23 — — US disclosed
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF SUNDANCE BIOSCIENCES, INC. 2024-01-25 — — US disclosed
CN-114507177-B Method for preparing functionalized 2- (3-oxo-isoindoline-1-subunit) methyl acetate from carbon dioxide 常州大学 2023-11-21 — — CN disclosed
WO-2023020291-A1 COMBINED USE OF IN10018 AND PLD 应世生物科技(南京)有限公司 2023-02-23 — — WO disclosed
CN-115697993-A Pyrimidines as AXL inhibitors 南京正大天晴制药有限公司 2023-02-03 — — CN disclosed
EP-4058015-A1 ALLOSTERIC EGFR INHIBITORS AND METHODS OF USE THEREOF Dana-Farber Cancer Institute, Inc. (US) 2022-09-21 — — EP disclosed
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS FORMA THERAPEUTICS, INC. 2022-09-08 — — US disclosed
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER THE BROAD INSTITUTE, INC. 2022-07-21 — — US disclosed
CN-114507177-A Method for preparing functionalized 2- (3-oxoisoindoline-1-subunit) methyl acetate from carbon dioxide 常州大学 2022-05-17 — — CN disclosed
US-20220089549-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES (PADS) AND METHODS OF PREPARATION AND USE THEREOF UNIV MASSACHUSETTS (US) 2022-03-24 — — US disclosed
WO-2022042591-A1 NITRILE DERIVATIVE THAT ACTS AS INHIBITOR OF DIPEPTIDYL PEPTIDASE 1 AND USE THEREOF 四川海思科制药有限公司 2022-03-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220226279-A1 ACYL SULFONAMIDES FOR TREATING CANCER KAT6A, KAT6B, KAT2A KMT2A 23/4885NPC1 3298/4885RAB9A 1471/4885
US-12357603-B2 Acyl sulfonamides for treating cancer KAT6A, KAT6B, KAT2A KMT2A 23/4885NPC1 3298/4885RAB9A 1471/4885
US-20240327412-A1 FACTOR XIIA INHIBITORS F11, F13B, F12 KMT2A 2640/4885NPC1 3064/4885RAB9A 2183/4885
US-20220089549-A1 INHIBITORS OF PROTEIN ARGININE DEIMINASES (PADS) AND METHODS OF PREPARATION AND USE THEREOF PADI2, PADI1, PADI4 KMT2A 1299/4885NPC1 4872/4885RAB9A 3542/4885
US-20220281869-A1 PURINONES AS UBIQUITIN-SPECIFIC PROTEASE 1 INHIBITORS USP1, UBA1, UBXN1 KMT2A 2234/4885NPC1 3141/4885RAB9A 1709/4885
US-20260069605-A1 KRAS INHIBITORS KRAS, NRAS, HRAS KMT2A 3566/4885NPC1 286/4885RAB9A 163/4885
US-12043623-B2 Purinones as ubiquitin-specific protease 1 inhibitors USP1, UBA1, UBXN1 KMT2A 2234/4885NPC1 3141/4885RAB9A 1709/4885
US-20240025906-A1 KINASE MODULATORS AND METHODS OF USE THEREOF TYK2, JAK1, JAK3 KMT2A 612/4885NPC1 4600/4885RAB9A 3465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.